Zacks Investment Research lowered shares of Liquidia Technologies (NASDAQ:LQDA) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

According to Zacks, “Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company’s product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States. “

LQDA has been the topic of a number of other reports. Needham & Company LLC assumed coverage on Liquidia Technologies in a report on Monday, August 20th. They issued a buy rating and a $30.00 price target on the stock. Jefferies Financial Group assumed coverage on Liquidia Technologies in a report on Thursday, November 8th. They issued a buy rating and a $27.00 price target on the stock. Cowen set a $40.00 price target on Liquidia Technologies and gave the company a buy rating in a report on Wednesday, October 31st. Finally, Wedbush assumed coverage on Liquidia Technologies in a report on Tuesday, September 4th. They issued an outperform rating and a $26.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Liquidia Technologies presently has an average rating of Buy and a consensus price target of $36.50.

Shares of Liquidia Technologies stock traded down $0.65 during trading on Wednesday, reaching $23.94. The stock had a trading volume of 10 shares, compared to its average volume of 27,749. Liquidia Technologies has a 52 week low of $10.52 and a 52 week high of $38.46. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.27 and a current ratio of 6.27.

Liquidia Technologies (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, October 31st. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.26). The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.03 million. Equities research analysts expect that Liquidia Technologies will post -7.32 EPS for the current year.

Institutional investors have recently modified their holdings of the company. TIAA CREF Investment Management LLC bought a new stake in shares of Liquidia Technologies in the third quarter valued at about $336,000. Laurion Capital Management LP bought a new stake in shares of Liquidia Technologies in the third quarter valued at about $480,000. Dean Capital Investments Management LLC bought a new stake in Liquidia Technologies during the third quarter worth about $1,483,000. Vanguard Group Inc. bought a new stake in Liquidia Technologies during the third quarter worth about $4,263,000. Finally, BlackRock Inc. bought a new stake in Liquidia Technologies during the third quarter worth about $5,924,000. Institutional investors own 27.07% of the company’s stock.

Liquidia Technologies Company Profile

Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.

Read More: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Liquidia Technologies (LQDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.